pharmaphorum.com
Takeda backs biomarker trial for Crohn's prevention
If successful, validated biomarkers and a blood risk score could allow clinicians to identify people at high risk of developing Crohn's disease and eventually test interventions to prevent symptoms. Prevention-focused research could shift how IBD is managed long-term rather than treating established disease only.
People with a family history of Crohn's disease, researchers and clinicians focused on IBD biomarkers and prevention, and patient advocates interested in early-detection strategies.
What To Know
A new EU- and industry-backed project called INTERCEPT will recruit 10,000 healthy first-degree relatives of people with Crohn's disease to validate blood-based biomarkers and build a risk score intended to predict Crohn's onset. About 80 people at highest predicted risk will be enrolled in an intervention trial to test whether disease can be prevented.
The project cites candidate blood proteins (ITGAV, EpCAM, IL-18, SLAMF7, IL-8) discovered by the IBD-Character Consortium and is funded by the Innovative Health Initiative with backing from Takeda. The trial is primarily a prevention and biomarker-validation study rather than a confirmatory drug efficacy trial.
The goal is to identify and validate predictors of future Crohn's disease and then test a prevention strategy in a small high-risk group, which could inform future larger prevention efforts.
This is early-stage translational research: it aims to build and validate a predictive blood risk score and to test whether intervening in people identified as high-risk can stop symptomatic disease from developing. It does not report results or recommend any changes in care today.
This is a funded, multi-country prevention trial and biomarker-validation effort but does not yet report outcomes. The INTERCEPT study will first validate biomarkers and risk scoring in a large cohort; only a small high-risk subgroup will receive an intervention. Results, timelines, and the nature of the preventive treatment were not detailed in the article.
